However, in a cohort which includes low grade gliomas [10], significant survival benefits were observed for patients with low EZH2, PHF19, CBX8 and PHC2 expression, and high CBX7, CBX6, RYBP and EZH1 expression (Figure S2). This evidence concerns the gene EZH1 and glioma.